Allogeneic Mesenchymal Stem Cells for Osteoarthritis
This study is ongoing, but not recruiting participants.
Sponsor:
Stempeutics Research Pvt Ltd
Collaborator:
Stempeutics Research Malaysia SDN BHD
Information provided by (Responsible Party):
Stempeutics Research Pvt Ltd
ClinicalTrials.gov Identifier:
NCT01448434
First received: September 20, 2011
Last updated: October 1, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is designed to know the safety and efficacy of 2 different doses of mesenchymal stem cells in patients suffering from osteoarthritis of knee joint.
| Condition | Intervention | Phase |
|---|---|---|
|
Osteoarthritis of Knee Joint |
Biological: Ex- vivo cultured adult allogeneic MSCs Biological: Plasmalyte-A |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee |
Resource links provided by NLM:
MedlinePlus related topics:
Osteoarthritis
Drug Information available for:
Normosol R
U.S. FDA Resources
Further study details as provided by Stempeutics Research Pvt Ltd:
Primary Outcome Measures:
- Number and percentage of patients with adverse events as a measure of safety and tolerability [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
- Safety evaluation will include assessment of physical examination, periodic monitoring of vital signs (heart rate, respiratory rate, blood pressure and temperature), clinical laboratory investigations (including haematology, serum chemistry, LFT, urine-analysis) and 12-lead ECG recording.
- Tolerability: Adverse events monitored using information volunteered by the patients and as observed by the PI will be summarized descriptively by total number of AE(s) and compared between the study arms.
Secondary Outcome Measures:
- Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
- Change from baseline in WOMAC OA stiffness index [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
- Change from baseline in WOMAC OA composite index [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
- Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain) [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
- Change from baseline in radiographic (X-ray) findings of knee [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
- Change from baseline in the WORMS score of knee using MRI [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
- Change from baseline in arthritis pain scores on the visual analogue scale [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
- Reduction in the intake of analgesic tablets from baseline [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 72 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | February 2013 |
| Estimated Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Ex- vivo cultured adult allogeneic MSCs
Single intraarticular dose of allogeneic MSCs
|
Biological: Ex- vivo cultured adult allogeneic MSCs
Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
|
|
Placebo Comparator: Plasmalyte-A
Single intraarticular dose of 2ml Plasmalyte
|
Biological: Plasmalyte-A
Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
|
Eligibility| Ages Eligible for Study: | 20 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Males or females in the age 20 - 70 years (both inclusive)
- Radiographic evidence of grade 2 to 3 osteoarthritis based on the Kellgren and Lawrence radiographic entry criteria.
- History of primary idiopathic osteoarthritis of the knee characterized by pain which requires intake of analgesics.
- Self-reported difficulty in at least one of the following activities attributed to knee pain: lifting and carrying groceries, walking 400 metres, getting in and out of a chair, or going up and down stairs.
- Patients who have been on stable medication for the past three months.
- Patients who have not received intra articular steroids or hyaluronan within the last three months.
- Female patients of childbearing age must be willing to use accepted methods of contraception during the course of the study
- Ability to provide written informed consent.
Exclusion Criteria:
- Prior or ongoing medical conditions (e.g., concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.
- History of surgery, including arthroscopy, or major trauma to the study joint in the previous 12 months
- Signs of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination
- Infections in or around the knee.
- Patients awaiting a replacement knee or hip joint
- Patients with other conditions that cause pain
- Significantly incapacitated or disabled and would be categorized as ACR Functional Class IV (largely or wholly incapacitated), or unable to walk without assistive devices
- Patients with other known rheumatic or inflammatory disease such as rheumatoid arthritis
- Other pathologic lesions on x-rays of knee
- Positive hepatitis B surface antigen, hepatitis C antibody test, Anti human immunodeficiency virus (HIV) antibody test, or VDRL
- History of Bleeding disorders
- Known hypersensitivity to Hyaluronan products or animal sera
- For women of child-bearing potential: positive pregnancy test or lactating
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01448434
Locations
| Malaysia | |
| Pantai Cheras Medical Centre | |
| Kuala Lumpur, Federal territory, Malaysia, 56100 | |
| KPJ Ampang Puteri Specialist Hospital | |
| Kuala Lumpur, Selangor, Malaysia, 68000 | |
| Serdang Hospital | |
| Kuala Lumpur, Selangor, Malaysia, 43300 | |
| Selayang Hospital | |
| Kuala Lumpur, Selangor, Malaysia, 68100 | |
Sponsors and Collaborators
Stempeutics Research Pvt Ltd
Stempeutics Research Malaysia SDN BHD
Investigators
| Principal Investigator: | Prof. Dr. Muhammad Ali Noor Muhd Abdul Ghani, FRCS | KPJ Ampang Puteri Specialist Hospital |
| Principal Investigator: | Dr. Ahmad Hisham Abd. Rashid, MD., MS | Serdang Hospital |
| Principal Investigator: | Dr. Suntharalingam Subramaniam, FRCS | Pantai Cheras Medical Centre |
| Principal Investigator: | Dato' Dr. Ramli Baba, MS | Selayang Hospital |
More Information
No publications provided
| Responsible Party: | Stempeutics Research Pvt Ltd |
| ClinicalTrials.gov Identifier: | NCT01448434 History of Changes |
| Other Study ID Numbers: | SRM/OA/10-11/001 |
| Study First Received: | September 20, 2011 |
| Last Updated: | October 1, 2012 |
| Health Authority: | Malaysia: Ministry of Health |
Keywords provided by Stempeutics Research Pvt Ltd:
|
Osteoarthritis Knee Stem cell MSC |
Additional relevant MeSH terms:
|
Osteoarthritis Osteoarthritis, Knee Arthritis |
Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013